IRVINGTON, NY--(Marketwire - June 11, 2008) - Electro-Optical Sciences, Inc. (“EOS”) (NASDAQ: MELA), a medical device company focused on the design and development of MelaFind®, a non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma, today provided an update on the MelaFind clinical trials program and Premarket Approval (PMA) preparation plans.
